Great Bay Bio Announces Its First AI-enabled Bioprocessing Platform-Klone 4.0, Reducing Cell Line Development Time and Cost by Up to 80%

Created on:2020-11-06 09:42

logo

November 6th,2020 Press Release

 

Great Bay Bio Announces Its First AI-enabled Bioprocessing Platform-Klone 4.0, Reducing Cell Line Development Time and Cost by Up to 80%

 

[2020/11/6, Dongguan] Klone 4.0 accomplishes both in a manner that could potentially disrupt the bioprocessing industry, firstly by reducing development times by up to 80% as AI eliminates many of the laboratory pain points through GBB's proprietary deep machine learning techniques and algorithms and then by locating those cells with the highest expression capability in record time, in fact, approximately four hours. 

Values of Klone 4.0

 

1. Higher Expression: Deep machine learning and AI intelligent prediction make it easier to find cells with high expression.

 

2.  Up to 12 Times More Cell Line Candidates: Based upon September 2020 customer proof-of-concept data. Twenty-five (25) higher-yielding cell lines were derived using Klone 4.0 as compared to two (2) from a traditional cell line development method from the same cell pool. This surprise result goes beyond industry standards, providing customers with more options and more possibilities. Note: Individual results may vary, depending upon cell pool.

 

3. Stability Prediction: In the industry, we have pioneered to utilize deep machine learning to predict cell line stability in a short time.

 

4. Simple and Cost-effective Process: With "time and cost-saving" written into its DNA, AI delivered extraordinary fruits in cell line development for GBB, and GBB hopes to set a new industry standard and perhaps a new milestone in medicine by – bringing cures to the market faster while lowering patient costs.

 

International market price: US $100K/order

 

 

About Great Bay Bio

Headquartered in Hong Kong, GBB is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to CMC (Chemistry, Manufacturing, Control) for development of biopharmaceuticals and other blue ocean bio-products (such as cell therapy), ultimately solving numerous pain points of CMC development, including high failure rates, long development timeline and high costs. Since the company’s establishment, it has obtained massive data from conventional biologics development in its 3100 m2 CMC facilities in Dongguan, PRC. With over RMB 300M investment, the facilities bolster advance equipment from world-renowned manufacturers. GBB has also successfully brought a number of biologic products to NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created the intelligent centralized database, where deep learning is being performed to create next generation AI-enabled CMC platforms. To learn more, please visit http://www.greatbay-bio.com.

 

PR Contact: Miss Liu 

Email: yt.liu@greatbay-bio.com

Home    News    Great Bay Bio Announces Its First AI-enabled Bioprocessing Platform-Klone 4.0, Reducing Cell Line Development Time and Cost by Up to 80%
PV:0
Collect